Effect and safety of telmisartan and amlodipine in treatment of hypertension complicated with diabetes：a Meta-analysis
10.3969/j.issn.1005-1678.2016.04.64
- VernacularTitle:替米沙坦对比氨氯地平治疗高血压合并糖尿病的疗效和安全性的Meta分析
- Author:
Ping GU
;
Min CHEN
;
Jinqi LI
;
Rongsheng TONG
- Publication Type:Journal Article
- Keywords:
telmisartan;
amlodipine;
hypertensiondiabetes;
Meta-analysis
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(4):203-206
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically evaluate the efficacy and safety of telmisartan and amlodipine in treatment of hypertension complicated with diabetes.Methods Retrieved from PubMed, EMBASE, Cochrane library, CNKI, VIP and Wanfang database by computer, randomized controlled trials( RCTs) about telmisartan versus amlodipine in treatment of hypertension and diabetes were collected, then relevant date were extracted, Meta-analysis was drawn by RevMan 5.3 statistical software.Results A total of 11 RCTs were included involving 914 patients.The results of Meta-analysis revealed that telmisartan was better than amlodipine in fasting blood glucose reduction[MD =-0.54,95%CI( -0.87, -0.21),P =0.001], glycosylated hemoglobinreduction[MD=-0.60,95%CI( -1.12,-0.07),P =0.03] and HOMA insulin resistance index reduction[MD =-1.27, 95%CI( -1.81,-0.73),P<0.001],there were statistical significance.There were no significant difference in systolic blood pressure[MD =2.39, 95%CI( -0.21,4.98),P=0.07],diastolic blood pressure[MD =0.17,95%CI( -0.95,1.29),P =0.77] and adverse drug reaction[RR=0.70, 95%CI(0.41,1.19),P=0.19].Conclusion For patients with hypertension and diabetes, telmisartan in decreasing fasting blood glucose, glycosylated hemoglobinand HOMA insulin resistance index is more effective than that of amlodipine, blood pressure in patients with equivalent,antihypertensive and safety are similar.
